Participate in a Study

register_now_copy

Current Studies

Cardiac Trials

Study – EX4758

  • eGFR ≥15 and < 60 mL/min/1.73 m2
  • Serum hs-CRP ≥2 mg/L at screening
  • Evidence of ASCVD by one or more of the following within the last 5 years from screening:
    • Coronary heart disease defined as at least one of the following:
    • Cerebrovascular disease defined as at least one of the following:
    • Symptomatic peripheral artery disease (PAD) defined as at least one of the following:

Type 2 Diabetes Trials:

Study - NN4352

  • Male or female, age ≥18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus ≥ 10 years prior to the day of screening.
  • HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).

Study - NN4592

  • Male or female and age above or equal to 18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
  • HbA1c of 7.0-10.0%
  • Insulin naïve. The following exceptions are permitted: short term insulin treatment for a maximum of 14 days before screening and/or prior insulin treatment for gestational diabetes.
  • Treated with stable doses of daily or weekly GLP-1 receptor agonist (excluding once weekly semaglutide with doses higher than 1.0 mg) according to local label for the treatment of diabetes ≥ 90 days before screening.
  • Body mass index (BMI) ≤ 40.0 kg/m2 .

Study - NN4593

  • Male or female and age above or equal to 18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
  • HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
  • Treated with once daily or twice-daily basal insulin (neutral protamine hagedorn insulin, insulin
  • Body mass index (BMI) ≤ 40.0 kg/m2.

Type 1 or 2 Diabetes Trials:

Study – CIP331

  • Individual is 2-80 years of age at time of consent
  • A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator for:
    • at least the last 6 months for subjects 2-6 years of age
    • at least the last 12 months for subjects 7-80 years of age
  • Subject is on multiple daily injection therapy
  • Subject is currently using or is willing to use the Guardian Connect system during the study
  • Subject agrees to comply with the study protocol requirements

Study – CIP322

  • Individual is 2-75 years of age at time of enrollment.
  • Subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
  • Subject is using insulin to treat their diabetes.
  • Subject agrees to comply with the study protocol requirements.
  • Subject is willing to perform SMBG approximately every 15 minutes /20 minutes during FST.
  • If subject is participating in YSI FST, subject has adequate venous access as assessed by investigator or appropriate staff.

Study – NN4635

  • Male or female, age above or equal to 18 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes mellitus ≥ 180 days prior to the day of screening
  • HbA1c of 8.0-10.5%
  • BMI ≥ 25 kg/m2
  • Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:
    • No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:
      • * Metformin
      • * Sulfonylureas
      • * SGLT2 inhibitors
      • *DPP-4 inhibitors
 
Endocrine Research Solutions, Inc.
1475 Holcomb Bridge Road, Suite 129, Roswell, GA 30076
Ph: 678.878.4750 Fx: 678.878.4751